About Tolemy Bio

This biotechnology company programs cell metabolism to optimize biomanufacturing processes. They use metabolic modeling and minimal data to design custom cell culture media, enabling efficient production of advanced therapies.

```xml <problem> Cell and gene therapy manufacturing faces challenges in optimizing cell culture media for efficient production and desired cell phenotypes. Traditional media development is slow, often taking years, and may not adequately address the complex metabolic requirements of specific cell types and processes. This can lead to suboptimal cell growth, function, and therapeutic efficacy. </problem> <solution> Tolemy Bio provides custom cell culture media design services, leveraging metabolic modeling and minimal data to optimize biomanufacturing processes for cell and gene therapies. The company employs AI and machine learning to analyze metabolite consumption and cell performance data, pinpointing the cells' metabolic state and designing optimized media formulations. This approach enables rapid development of tailored media solutions that enhance cell growth, function, and critical quality attributes (CQAs), ultimately improving the efficiency and efficacy of advanced therapy manufacturing. Tolemy Bio offers an end-to-end solution, including process characterization, model-driven media optimization, and small-batch media manufacturing with rigorous quality control. </solution> <features> - AI and ML-driven media optimization using advanced data analytics and proprietary computational frameworks - Rapid development timelines, delivering optimized media formulations within weeks - Custom media design tailored to specific cell types, target outcomes, and process needs - Small-batch media manufacturing for R&D and pre-clinical phases - Process characterization to map the existing metabolic state of cells - Optimization of media composition to drive targeted phenotypic changes, such as enhanced growth and improved endurance markers - In-house quality control and validation to meet stringent requirements - Milestone-based media licensing to minimize risk </features> <target_audience> Tolemy Bio serves cell and gene therapy manufacturers, including those working with CAR-T, CAR-NK cells, stem cells (HSCs, MSCs, iPSCs), and HEK293 cells producing AAV and LVV. </target_audience> ```

What does Tolemy Bio do?

Where is Tolemy Bio located?

Tolemy Bio is based in Cambridge, United Kingdom.

When was Tolemy Bio founded?

Tolemy Bio was founded in 2024.

Location

Cambridge, United Kingdom

Founded

2024

Employees

2 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Tolemy Bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

tolemy.bio 1K+

Founded 2024 – Cambridge, United Kingdom

Funding

No funding information available.

Team (<5)

No team information available.

Company Description

Problem

Cell and gene therapy manufacturing faces challenges in optimizing cell culture media for efficient production and desired cell phenotypes. Traditional media development is slow, often taking years, and may not adequately address the complex metabolic requirements of specific cell types and processes. This can lead to suboptimal cell growth, function, and therapeutic efficacy.

Solution

Tolemy Bio provides custom cell culture media design services, leveraging metabolic modeling and minimal data to optimize biomanufacturing processes for cell and gene therapies. The company employs AI and machine learning to analyze metabolite consumption and cell performance data, pinpointing the cells' metabolic state and designing optimized media formulations. This approach enables rapid development of tailored media solutions that enhance cell growth, function, and critical quality attributes (CQAs), ultimately improving the efficiency and efficacy of advanced therapy manufacturing. Tolemy Bio offers an end-to-end solution, including process characterization, model-driven media optimization, and small-batch media manufacturing with rigorous quality control.

Features

AI and ML-driven media optimization using advanced data analytics and proprietary computational frameworks

Rapid development timelines, delivering optimized media formulations within weeks

Custom media design tailored to specific cell types, target outcomes, and process needs

Small-batch media manufacturing for R&D and pre-clinical phases

Process characterization to map the existing metabolic state of cells

Optimization of media composition to drive targeted phenotypic changes, such as enhanced growth and improved endurance markers

In-house quality control and validation to meet stringent requirements

Milestone-based media licensing to minimize risk

Target Audience

Tolemy Bio serves cell and gene therapy manufacturers, including those working with CAR-T, CAR-NK cells, stem cells (HSCs, MSCs, iPSCs), and HEK293 cells producing AAV and LVV.